FDA clears Travere’s FILSPARI for expanded use in rare kidney disease

Nihon Kohden launches Life Scope E7 patient monitoring platform in India

CDSCO-cleared BSM-5700 series targets ICU, NICU, ER, OR and digital health integration under ABDM

FDA presses 2,200+ companies to fix missing clinical trial results

Move amid evidence of widespread reporting gaps

Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations

The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access

CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi

Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews

Roche wins CE mark for blood-based MS brain damage test

The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain

Pharma firms accelerate regional GLP-1 capacity to de-risk supply chains amid geopolitical tensions: GlobalData

At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy

GE HealthCare and Medtronic launch real-time brain surgery imaging integration

The Stealth AXiS surgical navigation system was recently cleared by the US Food and Drug Administration (FDA) for cranial procedures in the United States

Eli Lilly launches once-daily weight-loss pill Foundayo

The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions